BRIEF-GSK's Depemokimab Accepted For Review In China, Japan
ReutersJan 28, 2025 7:22 AM
Jan 28 (Reuters) - GSK plc GSK.L:
GSK PLC - DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN
Source text: ID:nRSb8470Ua
Further company coverage: GSK.L
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.TradingKey
18 hours ago
.jpg)
Crypto Stocks Ignite ARKK’s Q2 NAV Surge of 46.96%
ARK Innovation ETF (ARKK), managed by Cathie Wood, delivered a stellar performance in Q2 2025, with its net asset value (NAV) soaring by 46.96%, reaffirming Wood’s reputation as one of Wall Street’s most polarizing yet influential fund managers.TradingKey
20 hours ago
U.S. July CPI Commentary: Obstacles Cleared, Where Will U.S. Stocks Go Next?
TradingKey - On 12 August 2025, the United States released its Consumer Price Index (CPI) data for July. In terms of headline inflation, the CPI rose by 2.7% year-on-year in the month, slightly lower than the expected 2.8%. However, core CPI climbed 3.1% year-on-year, edging past the projected 3.0%.TradingKey
Wed, Aug 13
.jpg)
